Cooley strengthens litigation team with Finnegan duo
Cooley has grown its IP litigation practice with the addition of partners Sanya Sukduang and Jonathan Davies, who will be based in Washington, DC.
Arriving from Finnegan, Henderson, Farabow, Garrett & Dunner, Sukduang and Davies focus on life sciences with an emphasis on pharmaceutical litigation, including Hatch‐Waxman Abbreviated New Drug Application (ANDA) litigation.
“Sanya’s and Jonathan’s experience navigating complex ANDA cases adds significant depth to the life sciences component of our IP litigation practice and complements the work done by our patent counselling and life sciences partnering practice groups,” said Stephen Smith, chair of Cooley's IP litigation practice.
“Together, their experience will prove an invaluable asset to our clients, particularly the increasing number of them with later-stage products ripe for ANDA litigation.”
Sukduang advises clients on patent litigation before federal district courts and the US Court of Appeals for the Federal Circuit, as well as proceedings before the Patent Trial and Appeal Board. His work centres on litigating ANDA matters, challenges for brand drug manufacturers, diagnostic methods, biological products and medical devices.
He also formerly chaired Finnegan’s diversity and inclusion committee.
“We know firsthand how high stakes ANDA litigation is for the innovative companies we advise,” said Sukduang. “We are excited about the opportunities we’ll be able to provide our clients with the support of Cooley’s powerful IP litigation platform.”
Davies’ practice centres on pharmaceutical and biotechnology cases, including Hatch‐Waxman litigation related to ANDAs and biologics litigation under the Biologics Price Competition and Innovation Act.
“We look forward to delivering successful results for our clients as we team up with our new colleagues,” said Davies.
Cooley claims one of the most active patent litigation practices in the US, having handled more than 525 patent cases and more than 70 Federal Circuit patent appeals in the past five years, the majority as the appellee.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
